Related Experiment Video
Updated: Jul 1, 2025
08:35
Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
Published on: May 26, 2022
3.2K
Resistant hypertension
Farnoosh Shariati1, Nitin Tandan, Carl J Lavie
1Ochsner Heart and Vascular Institute, Ochsner Clinical School - The University of Queensland School of Medicine, New Orleans, Louisiana, USA.
Current Opinion in Cardiology
|March 8, 2024
Summary
Resistant hypertension (RH) management is evolving. Device-based treatments targeting the sympathetic nervous system show promise for reducing cardiovascular risks in patients with RH.
Area of Science:
- Cardiology
- Nephrology
- Internal Medicine
Background:
- Resistant hypertension (RH) is defined as uncontrolled blood pressure despite optimal doses of three antihypertensive drugs, including a diuretic.
- RH significantly increases the risk of cardiovascular morbidity and mortality.
- It places a substantial burden on global healthcare systems.
Purpose of the Study:
- To provide a comprehensive overview of resistant hypertension.
- To review current diagnostic strategies for RH.
- To discuss therapeutic approaches for managing RH.
Main Methods:
- Literature review of diagnostic criteria for RH.
- Analysis of recent clinical studies on RH management.
- Evaluation of device-based therapies targeting sympathetic nervous system outflow.
Main Results:
- Device-based treatments for RH demonstrate promising results in reducing sympathetic nervous system activity.
- These interventions may lead to a decrease in adverse cardiovascular outcomes for patients with RH.
- Current diagnostic and therapeutic strategies are being refined.
Conclusions:
- Resistant hypertension requires a multifaceted management approach.
- Device-based therapies represent a promising avenue for RH treatment.
- Further research is ongoing to optimize the care of patients with RH.
Related Concept Videos
01:18Hypertension and Regulation of Blood Pressure
2.1K
Hypertension, the most common cardiovascular disease, is diagnosed through repeated measurements of elevated blood pressure. Its risks, including damage to the kidney, heart, and brain, are directly proportional to blood pressure levels. Starting from 115/75 mm Hg, the risk of cardiovascular disease doubles with each increment of 20/10 mm Hg. The diagnosis relies on blood pressure measurements, not on patient symptoms, as hypertension is often asymptomatic until end-organ damage is imminent or...
2.1K
01:30Antihypertensive Drugs: Angiotensin II Receptor Blockers
730
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
730
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
429
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
429
01:25Antihypertensive Drugs: Direct Renin Inhibitors
625
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
625
01:30Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
636
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
636
01:28Antihypertensive Drugs: Potassium-Sparing Diuretics
545
Liddle syndrome is a genetically inherited form of hypertension characterized by the overactivity of epithelial sodium channels in the nephron, the functional unit of the kidney. This heightened activity leads to increased sodium reabsorption and excessive excretion of potassium. To counteract this, potassium-sparing diuretics such as amiloride are used. They function by blocking these sodium channels, thereby reducing the influx of sodium into the epithelial cells and minimizing the loss of...
545